Advertisement

Insulin-Like Growth Factors and Endocrine Neoplasia

  • Douglas Yee
  • Adrian V. Lee
Part of the Contemporary Endocrinology book series (COE)

Abstract

The observation that breast (BC) and prostate cancer (PC) are regulated by sex hormones provided a paradigm for treatment of these diseases (1,2). Despite the accumulation of multiple genetic abnormalities, the cancer cell is still responsive to extracellular signals that were previously required for normal growth and development of the organ. Blockade of steroid hormone receptors, or inhibition of the synthesis of the ligands for the receptors, are successful and relatively nontoxic therapeutic modalities for treatment of virtually all stages of BC and PC (3,4). Thus, it is a worthwhile effort to define other growth regulatory pathways important for cancer cells, with the long-term goal of developing additional specific therapies. This chapter discusses the evidence that the insulinlike growth factors (IGFs) regulate cancer cell growth, and that strategies directed at inhibition of IGF action could be useful therapeutic strategies for cancer treatment.

Keywords

Human Breast Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Huggins C, Hodges CV. Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphtases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.Google Scholar
  2. 2.
    Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104–107.Google Scholar
  3. 3.
    Small EJ. Update on the diagnosis and treatment of prostate cancer. Curr Opin Oncol 1998; 10: 244–252.PubMedGoogle Scholar
  4. 4.
    Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974–984.PubMedGoogle Scholar
  5. 5.
    Salmon WD, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825–836.PubMedGoogle Scholar
  6. 6.
    Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68–91.PubMedGoogle Scholar
  7. 7.
    Laron Z. Laron-type dwarfism (hereditary somatomedin deficiency): a review. Adv Intern Med Pediatr 1984; 51: 117.Google Scholar
  8. 8.
    Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor-I (IGF-1) and type-1 IGF receptor (IGF1r). Cell 1993; 75: 59–72.PubMedGoogle Scholar
  9. 9.
    Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73–82.PubMedGoogle Scholar
  10. 10.
    Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pittsmeek S, Dalton D, Gillett N, Stewart TA. IGF-I is required for normal embryonic growth in mice. Gene Dev 1993; 7: 2609–2617.PubMedGoogle Scholar
  11. 11.
    Liu JL, Grinberg A, Westphal H, Sauer B, Accili D, Karas M, LeRoith D. Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. Mol Endocrinol 1998; 12: 1452–1462.PubMedGoogle Scholar
  12. 12.
    Woods KA, Camacho-Hubner C, Barter D, Clark AJ, Savage MO. Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatr 1997; 423 (Suppl): 39–45.Google Scholar
  13. 13.
    Beck KD, Powellbraxton L, Widmer HR, Valverde J, Hefti F. Igfl gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 1995; 14: 717–730.PubMedGoogle Scholar
  14. 14.
    DeChiara TM, Efstratiadis A, Robertson EJ. A growth deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene distributed by targeting. Nature 1990; 345: 78–80.PubMedGoogle Scholar
  15. 15.
    DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849–859.PubMedGoogle Scholar
  16. 16.
    LeRoith D. Seminars in medicine of the Beth Israel Deaconess Medical Center: insulin-like growth factors. N Engl J Med 1997; 336: 633–640.Google Scholar
  17. 17.
    Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987; 329: 301–307.PubMedGoogle Scholar
  18. 18.
    Blanchard F, Raher S, Duplomb L, Vusio P, Pitard V, Taupin JL, et al. The mannose 6-phosphate/ insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor. J Biol Chem 1998;273:20, 886–20, 893.Google Scholar
  19. 19.
    Kang JX, Li YY, Leaf A. Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. Proc Nati Acad Sci USA 1997;94:13, 671–13, 676.Google Scholar
  20. 20.
    Nishimoto I, Murayama Y, Katada T, Ui M, Ogata E. Possible direct linkage of insulin-like growth factor II receptor with guanine nucleotide-binding protein. J Biol Chem 1989;264:14, 029–14, 038.Google Scholar
  21. 21.
    Kojima I, Nishimoto I, Iiri T, Ogata E, Rosenfeld R. Evidence that type II insulin-like growth factor receptor is coupled to calcium gating system. Biochem Biophys Res Commun 1988; 154: 9–19.PubMedGoogle Scholar
  22. 22.
    Okamoto T, Katada T, Murayama Y, Ui M, Ogata E, Nishimoto I. A simple structure encodes G protein-activating function of the IGF-II/mannose 6-phosphate receptor. Cell 1990; 62: 709–717.PubMedGoogle Scholar
  23. 23.
    Korner C, Nurnberg B, Uhde M, Braulke T. Mannose 6-phosphate insulin-like growth factor II receptor fails to interact with G-proteins: analysis of mutant cytoplasmic receptor domains. J Biol Chem 1995; 270: 287–295.PubMedGoogle Scholar
  24. 24.
    Schmidt B, Kieckesiemsen C, Waheed A, Braulke T, von Figura K. Localization of the insulin-like growth factor II binding site to amino acids 1508–1566 in repeat 11 of the mannose 6-phosphate/insulin-like growth factor II receptor. J Biol Chem 1995;270:14, 975–14, 982.Google Scholar
  25. 25.
    Braulke T, Causin C, Waheed A, Junghans U, Hasilik A, Maly P, Humbel RE, vonFigura K. Mannose 6-phosphate/insulin-like growth factor II receptor: distinct binding sites for mannose 6-phosphate and insulin-like growth factor II. Biochem Biophys Res Commun 1988; 150: 1287–1293.PubMedGoogle Scholar
  26. 26.
    Barlow DP, Stoger R, Herrmann BG, Saito K, Schweifer N. The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature 1991; 349: 84–87.PubMedGoogle Scholar
  27. 27.
    Stoger R, Kubicka P, Liu CG, Kafri T, Razin A, Cedar H, Barlow DP. Maternal-Specific methylation of the imprinted mouse igf2r locus identifies the expressed locus as carrying the imprinting signal. Cell 1993; 73: 61–71.PubMedGoogle Scholar
  28. 28.
    Xu Y, Goodyer CG, Deal C, Polychronakos C. Functional polymorphism in the parental imprinting of the human IGF2R gene. Biochem Biophys Res Commun 1993; 197: 747–754.PubMedGoogle Scholar
  29. 29.
    Smrzka OW, Fae I, Stoger R, Kurzbauer R, Fischer GF, Henn T, Weith A, Barlow DP. Conservation of a maternal-specific methylation signal at the human IGF2R locus. Hum Mol Genet 1995; 4: 1945–1952.PubMedGoogle Scholar
  30. 30.
    Giannoukakis N, Deal C, Paquette J, Kukuvitis A, Polychronakos C. Polymorphic functional imprinting of the human IGF2 gene among individuals, in blood cells, is associated with H 19 expression. Biochem Biophys Res Commun 1996; 220: 1014–1019.PubMedGoogle Scholar
  31. 31.
    Kalscheuer VM, Mariman EC, Schepens MT, Rehder H, Ropers HH. Insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. Nature Genet 1993: 5: 74–78.PubMedGoogle Scholar
  32. 32.
    Ogawa O, McNoe LA, Eccles MR, Morison IM, Reeve AE. Human insulin-like growth factor type I and type II receptors are not imprinted. Hum Mol Genet 1993; 2: 2163–2165.PubMedGoogle Scholar
  33. 33.
    Ullrich A, Gray A, Tam AW, Yang FT, Tsubokawa M, Collins C, et al. Insulin-like growth factor 1 receptor primary structure: comparison with insulin receptor suggests structural determinants that define hormonal specificity. EMBO J 1986; 5: 2503–2512.PubMedGoogle Scholar
  34. 34.
    Tollefsen SE, Stoszek RM, Thompson K. Interaction of the alpha-beta dimers of the insulin-like growth factor I receptor is required for receptor autophosphorylation. Biochemistry 1991; 30: 48–54.PubMedGoogle Scholar
  35. 35.
    Blakesley VA, Stannard BS, Kalebic T, Heiman LJ, LeRoith D. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 1997; 152: 339–344.PubMedGoogle Scholar
  36. 36.
    Esposito DL, Blakesley VA, Koval AP, Scrimgeour AG, LeRoith D. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 1997; 138: 2979–2988.PubMedGoogle Scholar
  37. 37.
    Xu SQ, Tang DH, Chamberlain S, Pronk G, Masiarz FR, Kaur S, et al. The granulin/epithelin precursor abrogates the requirement for the insulin-like growth factor 1 receptor for growth in vitro. J Biol Chem 1998;273:20, 078–20, 083.Google Scholar
  38. 38.
    Morrione A, Valentinis B, Xu SQ, Yumet G, Louvi A, Efstratiadis A, Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci USA 1997; 94: 3777–3782.PubMedGoogle Scholar
  39. 39.
    Morrione A, Valentinis B, Li SW, Ooi JYT, Margolis B, Baserga R. Grb10: a new substrate of the insulin-like growth factor i receptor. Cancer Res 1996; 56: 3165–3167.PubMedGoogle Scholar
  40. 40.
    Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55: 2463–2469.PubMedGoogle Scholar
  41. 41.
    Dey BR, Frick K, Lopaczynski W, Nissley SP, Furlanetto RW. Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, she, and grb10. Mol Endocrinol 1996; 10: 631–641.PubMedGoogle Scholar
  42. 42.
    Sun XJ, Wang L-M, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, et al. Role of IRS-2 in insulin and cytokine signalling. Nature 1995; 377: 173–177.PubMedGoogle Scholar
  43. 43.
    Beitner-Johnson D, Leroith D. Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. J Biol Chem 1995; 270: 5187–5190.PubMedGoogle Scholar
  44. 44.
    Koval AP, Karas M, Zick Y, LeRoith D. Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction. J Biol Chem 1998;273:14, 780–14, 787.Google Scholar
  45. 45.
    O’Neill TJ, Rose DW, Pillay TS, Hotta K, Olefsky JM, Gustafson TA. Interaction of a GRB-IR splice variant (a human GRB 10 homolog) with the insulin and insulin-like growth factor I receptors: evidence for a role in mitogenic signaling. J Biol Chem 1996;271:22, 506–22, 513.Google Scholar
  46. 46.
    White MF. IRS-signaling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998; 182: 3–11.PubMedGoogle Scholar
  47. 47.
    Federici M, Zucaro L, Porzio O, Massoud R, Borboni P, Lauro D, Sesti G. Increased expression of insulin/ insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects. J Clin Invest 1996; 98: 2887–2893.PubMedGoogle Scholar
  48. 48.
    Federici M, Porzio O, Zucaro L, Fusco A, Borboni P, Lauro D, Sesti G. Distribution of insulin/insulinlike growth factor-I hybrid receptors in human tissues. Mol Cell Endocrinol 1997; 129: 121–126.PubMedGoogle Scholar
  49. 49.
    Garrouste FL, RemacleBonnet MM, Lehmann MMA, Marvaldi JL, Pommier GJ. Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29–D4 human colonic carcinoma cells. Endocrinology 1997; 138: 2021–2032.PubMedGoogle Scholar
  50. 50.
    Kasuya J, Paz IB, Maddux BA, Goldfine ID, Hefta SA, Fujita-yamaguchi Y. Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification. Biochemistry 1993;32:13, 531–13, 536.Google Scholar
  51. 51.
    Langlois WJ, Sasaoka T, Yip CC, Olefsky JM. Functional characterization of hybrid receptors composed of a truncated insulin receptor and wild type insulin-like growth factor 1 or insulin receptors. Endocrinology 1995; 136: 1978–1986.PubMedGoogle Scholar
  52. 52.
    Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor a-subunit heterogeneity, evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 1989;264:13, 238–13, 244.Google Scholar
  53. 53.
    Seely BL, Reichart DR, Takata Y, Yip C, Olefsky JM. A functional assessment of insulin/insulin-like growth factor-I hybrid receptors. Endocrinology 1995; 136: 1635–1641.PubMedGoogle Scholar
  54. 54.
    Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K. Receptors for insulin and insulin-like growth factor-I can form hybrid dimers, characterisation of hybrid receptors in transfected cells. Biochem J 1990; 270: 383–390.PubMedGoogle Scholar
  55. 55.
    Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 1993; 290: 419–426.PubMedGoogle Scholar
  56. 56.
    Sakano K, Enjoh T, Numata F, Fujiwara H, Marumoto Y, Higashihashi N, et al. The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. J Biol Chem 1991;266: 20, 626–20, 635.Google Scholar
  57. 57.
    Baxter RC, Binoux MA, Clemmons DR, Conover CA, Drop SLS, Holly JMP, et al. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. J Clin Endocrinol Metab 1998; 83: 3213–3213.PubMedGoogle Scholar
  58. 58.
    Leong SR, Baxter RC, Camerato T, Dai J, Wood WI. Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding protein complex. Mol Endocrinol 1992; 6: 870–876.PubMedGoogle Scholar
  59. 59.
    Kubler B, Cowell S, Zapf J, Braulke T. Proteolysis of insulin-like growth factor binding proteins by a novel 50-kilodalton metalloproteinase in human pregnancy serum. Endocrinology 1998; 139: 1556–1563.PubMedGoogle Scholar
  60. 60.
    Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 1990; 71: 797–805.PubMedGoogle Scholar
  61. 61.
    Clemmons DR, Busby W, Clarke JB, Parker A, Duan C, Nam TJ. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Endocr J 1998; 45:S 1 - S8.Google Scholar
  62. 62.
    Valentinis B, Bhala A, Deangelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 1995; 9: 361–367.PubMedGoogle Scholar
  63. 63.
    Oh Y, Mueller HL, Pham Y, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 1993;268:26, 045–26, 048.Google Scholar
  64. 64.
    Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997;272:20, 572–20, 576.Google Scholar
  65. 65.
    Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein-1 stimulates cell migration and binds alpha5betal integrin by means of its arg-gly-asp sequence. Proc Natl Acad Sci USA 1993;90:10, 553–10, 557.Google Scholar
  66. 66.
    Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 1998;273:18, 347–18, 352.Google Scholar
  67. 67.
    Kim HS, Nagalla SR, Oh Y, Wilson E, Roberts CT Jr, Rosenfeld RG. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA 1997;94:12, 981–12, 986.Google Scholar
  68. 68.
    Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 1997;272:30, 729–30, 734.Google Scholar
  69. 69.
    Sell C, Dumneil G, Deveaud C, Miura M, Coppola D, DeAngeli T, et al. Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994; 14: 3604–3612.PubMedGoogle Scholar
  70. 70.
    Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus-40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993;90:11, 217–11, 221.Google Scholar
  71. 71.
    Valentinis B, Porcu P, Quinn K, Baserga R. The role of the insulin-like growth factor I receptor in the transformation by simian virus 40 T antigen. Oncogene 1994; 9: 825–831.PubMedGoogle Scholar
  72. 72.
    Coppola D, Ferber A, Miura M, Sell C, Dambrosio C, Rubin R, Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994; 14: 4588–4595.PubMedGoogle Scholar
  73. 73.
    Li SW, Resnicoff M, Baserga R. Effect of mutations at serines 1280–1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J Biol Chem 1996;271:12, 254–12, 260.Google Scholar
  74. 74.
    Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990; 10: 464–473.PubMedGoogle Scholar
  75. 75.
    Berns EMJJ, Klign JGM, van Staveren IL, Portengen H, Foekens JA. Sporadic amplification of the insulin-like growth factor I receptor gene in human breast tumors. Cancer Res 1992; 52: 1036–1039.PubMedGoogle Scholar
  76. 76.
    Valentinis B, Morrione A, Taylor SJ, Baserga R. Insulin-like growth factor I receptor signaling in transformation by src oncogenes. Mol Cell Biol 1997; 17: 3744–3754.PubMedGoogle Scholar
  77. 77.
    Parr T. Insulin exposure controls the rate of mammalian aging. Mech Ageing Dev 1996; 88: 75–82.PubMedGoogle Scholar
  78. 78.
    Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr 1991; 11: 393–412.PubMedGoogle Scholar
  79. 79.
    Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66: 1191–1308.PubMedGoogle Scholar
  80. 80.
    Hursting SD, Perkins SN, Brown CC, Haines DC, Phang JM. Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. Cancer Res 1997; 57: 2843–2846.PubMedGoogle Scholar
  81. 81.
    Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 4667–4672.PubMedGoogle Scholar
  82. 82.
    Hankins GR, Desouza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, Jirtle RL. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996; 12: 2003–2009.PubMedGoogle Scholar
  83. 83.
    Desouza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genet 1995; 11: 447–449.Google Scholar
  84. 84.
    Desouza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10: 1725–1729.Google Scholar
  85. 85.
    Rappolee DA, Sturm KS, Behrendtsen O, Schultz GA, Pedersen RA, Werb Z. Insulin-like growth factor-II acts through an endogenous growth pathway regulated by imprinting in early mouse embryos. Gene Dev 1992; 6: 939–952.PubMedGoogle Scholar
  86. 86.
    Haig D, Graham C. Genomic imprinting and the strange case of the insulin-like growth factor II receptor. Cell 1991; 64: 1045, 1046.Google Scholar
  87. 87.
    Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE. Relaxation of insulin-like growth factor-II gene imprinting implicated in Wilms’ tumour. Nature 1993; 362: 749–751.PubMedGoogle Scholar
  88. 88.
    Zhan SL, Shapiro DN, Helman Li. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994; 94: 445–448.PubMedGoogle Scholar
  89. 89.
    Rainier S, Dobry CJ, Feinberg AP. Loss of imprinting in hepatoblastoma. Cancer Res 1995; 55: 1836 1838.Google Scholar
  90. 90.
    Zhan SL, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in ewing’s sarcoma. Oncogene 1995; 11: 2503–2507.PubMedGoogle Scholar
  91. 91.
    Zhan SL, Shapiro D, Zhan SX, Zhang Li, Hirschfeld S, Elassal J, Heiman Li. Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. J Biol Chem 1995;270: 27, 983–27, 986.Google Scholar
  92. 92.
    Vu TH, Yballe C, Boonyanit S, Hoffman AR. Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J Clin Endocrinol Metab 1995; 80: 1670–1676.PubMedGoogle Scholar
  93. 93.
    Doucrasy S, Barrois M, Fogel S, Ahomadegbe JC, Stehelin D, Coll J, Riou G. High incidence of loss of heterozygosity and abnormal imprinting of h19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of hl9 and IGF2 expression and biallelic hypomethylation of h19. Oncogene 1996; 12: 423–430.Google Scholar
  94. 94.
    Yballe CM, Vu TH, Hoffman AR. Imprinting and expression of insulin-like growth factor-II and h19 in normal breast tissue and breast tumor. J Clin Endocrinol Metab 1996; 81: 1607–1612.PubMedGoogle Scholar
  95. 95.
    Nonomura N, Miki T, Nishimura K, Kanno N, Kojima Y, Okuyama A. Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors. J Urol 1997; 157: 1977–1979.PubMedGoogle Scholar
  96. 96.
    Wu HK, Squire JA, Catzavelos CG, Weksberg R. Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun 1997; 235: 123–129.PubMedGoogle Scholar
  97. 97.
    Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–565.PubMedGoogle Scholar
  98. 98.
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1373–1375.Google Scholar
  99. 99.
    Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk: interpreting the evidence. J Natl Cancer Inst 1998; 90: 876–879.PubMedGoogle Scholar
  100. 100.
    Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based; case-control study. J Natl Cancer Inst 1998; 90: 911–915.PubMedGoogle Scholar
  101. 101.
    Strohm O, Osterziel KJ, Dietz R. Insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 352: 488, 489.PubMedGoogle Scholar
  102. 102.
    Campagnoli C, Ambroggio S, Biglia N, Peris C, Sismondi P. Insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 352: 488.PubMedGoogle Scholar
  103. 103.
    Florkowski C, Livesey J, Espiner E. Insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 352: 489, 490.Google Scholar
  104. 104.
    Hankinson SE, Willett WC, Speizer FE, Pollak M. Insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 352: 488, 489.Google Scholar
  105. 105.
    Janssen JAMJL, Lamberts SWJ. Insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 352: 490.PubMedGoogle Scholar
  106. 106.
    Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors, IGF receptors, and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991; 73: 401–407.PubMedGoogle Scholar
  107. 107.
    Plymate SR, Tennant M, Birnbaum RS, Thrasher JB, Chatta G, Ware JL. The effect of the insulin-like growth factor system human prostate epithelial cells of immortalization and transformation by simian virus-40 t antigen. J Clin Endocrinol Metab 1996; 81: 3709–3716.PubMedGoogle Scholar
  108. 108.
    Toning N, Vinter-Jensen L, Pederson SB, Sorenson FB, Flyvbjerg A, Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of rat prostate. J Urol 1997; 158: 222–227.Google Scholar
  109. 109.
    Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes wand with an increase in IGF binding protein 3. Cancer Res 1998; 58: 215–218.PubMedGoogle Scholar
  110. 110.
    Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985; 313: 745–747.PubMedGoogle Scholar
  111. 111.
    Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995; 136: 5485–5492.PubMedGoogle Scholar
  112. 112.
    Connolly JM, Rose DP. Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 1994; 24: 167–175.PubMedGoogle Scholar
  113. 113.
    Figueroa JA, Lee AV, Jackson JG, Yee D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor binding protein-1: evidence for an IGF-II autocrine loop. J Clin Endocrinol Metab 1995; 80: 3476–3482.PubMedGoogle Scholar
  114. 114.
    Huynh H, Pollak M, Zhang JC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1;25(OH)2D3 and its analog EB1089. Int J Oncol 1998; 13: 137–143.PubMedGoogle Scholar
  115. 115.
    Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin-like growth factor-1: action and receptor characterization in human prostate cancer cell lines. Prostate 1993; 22: 243–252.PubMedGoogle Scholar
  116. 116.
    Matuo Y, Mishi N, Tanaka H, Sasaki I, Issacs JT, Wada F. Production of IGF-Il-related peptide by an anaplastic cell line (AT-3) established from the Dunning prostate carcinoma of rats. In Vitro Dev Biol 1988; 24: 1053–1056.Google Scholar
  117. 117.
    Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor-1. Cancer Res 1992; 52: 6447–6451.PubMedGoogle Scholar
  118. 118.
    Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor-1. Cancer Res 1993; 53: 1102–1106.PubMedGoogle Scholar
  119. 119.
    Damon SE, Maddison L, Ware JL, Plymate SR. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP); IGFBP-4; delays onset of prostate tumor formation. Endocrinology 1998; 139: 3456–3464.PubMedGoogle Scholar
  120. 120.
    Lamharzi N, Schally AV, Koppan M, Groot K. Growth hormone-releasing hormone antagonist MZ5–156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 1998; 95: 8864–8868.PubMedGoogle Scholar
  121. 121.
    Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996; 93: 7263–7268.PubMedGoogle Scholar
  122. 122.
    Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL. Reexpression of the type I insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 1997; 138: 1728–1735.PubMedGoogle Scholar
  123. 123.
    Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996; 81: 3774–3782.PubMedGoogle Scholar
  124. 124.
    Reinikainen P, Palvimo JJ, Janne OA. Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 1996; 137: 4351–4357.PubMedGoogle Scholar
  125. 125.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474–5478.PubMedGoogle Scholar
  126. 126.
    Rechler MM. Growth inhibition by insulin-like growth factor (IGF) binding protein-3: what’s 1GF got to do with it? Endocrinology 1997; 138: 2645–2647.PubMedGoogle Scholar
  127. 127.
    Rajah R, Valentinis B, Cohen P. Insulin like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 1997;272:12, 181–12, 188.Google Scholar
  128. 128.
    Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996; 137: 3206–3212.PubMedGoogle Scholar
  129. 129.
    Zadeh SM, Binoux M. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 1997; 138: 3069–3072.PubMedGoogle Scholar
  130. 130.
    Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046–1053.PubMedGoogle Scholar
  131. 131.
    Fielder PJ, Rosenfeld RG, Graves HCB, Grandbois K, Maack CA, Sawamura S, et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul 1994; 4: 164–172.PubMedGoogle Scholar
  132. 132.
    Bonnet P, Reiter E, Bruyninx M, Sente B, Dombrowicz D, Deleval J, Closset J, Hennen G. Benign prostatic hyperplasia and normal prostate aging: differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. J Clin Endocrinol Metab 1993; 77: 1203–1208.PubMedGoogle Scholar
  133. 133.
    Fiorelli G, De Bellis A, Longo A, Giannini S, Natali A, Costantini A, Vannelli GB, Serio M. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 1991; 72: 740–746.PubMedGoogle Scholar
  134. 134.
    Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J Clin Endocrinol Metab 1996; 81: 3783–3792.PubMedGoogle Scholar
  135. 135.
    Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996; 81: 411–420.PubMedGoogle Scholar
  136. 136.
    Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, et al. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998; 291: 469–479.PubMedGoogle Scholar
  137. 137.
    Monti S, DiSilverio F, Lanzara S, Varasano P, Martini C, TostiCroce C, Sciarra F. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens. Steroids 1998; 63: 362–366.PubMedGoogle Scholar
  138. 138.
    Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994; 79: 1410–1415.PubMedGoogle Scholar
  139. 139.
    Karey KP, Sirbasku DA. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res 1988; 48: 4083–4092.PubMedGoogle Scholar
  140. 140.
    Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994;269: 16, 433–16, 442.Google Scholar
  141. 141.
    Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SAW, Ramasharma K, Marshall M, Li CH. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 1989; 3: 1701–1709.PubMedGoogle Scholar
  142. 142.
    Lee AV, Darbre P, King RJ. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol 1994; 99: 211–220.PubMedGoogle Scholar
  143. 143.
    Stewart A. Johnson MD, May FEB, Westley BR. Role of insulin-like growth factors and the type 1 insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265:21, 172–21, 178.Google Scholar
  144. 144.
    McGuire W Jr, Jackson JG, Figueroa JA, Shimasaki SA, Powell DR, Yee D. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 1992; 84: 1336–1341.PubMedGoogle Scholar
  145. 145.
    Stewart A, Westley B, May F. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 1992; 66: 640–648.PubMedGoogle Scholar
  146. 146.
    Costantino A, Milazzo G, Giorgino F, Russo P, Goldfine ID, Vigneri R, Belfiore A. Insulin-resistant MDA-MB23 I human breast cancer cells contain a tyrosine kinase inhibiting activity. Mol Endocrinol 1993; 7: 1667–1676.PubMedGoogle Scholar
  147. 147.
    Sepp-Lorenzino L, Rosen N, Lebwohl DE. Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. Cell Growth Differ 1994; 5: 1077–1083.PubMedGoogle Scholar
  148. 148.
    Rubin R, Baserga R. Insulin-like growth factor-1 receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73: 311–331.PubMedGoogle Scholar
  149. 149.
    Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death: proliferative and antiapoptotic effects. Breast Cancer Res Treat 1998; 56: 1–10.Google Scholar
  150. 150.
    Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-l) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997; 57: 2687–2693.PubMedGoogle Scholar
  151. 151.
    Doerr ME, Jones JI. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996; 271: 2443–2447.PubMedGoogle Scholar
  152. 152.
    Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 1996; 93: 2482–2487.PubMedGoogle Scholar
  153. 153.
    Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett JC. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998; 58: 3353–3361.PubMedGoogle Scholar
  154. 154.
    Daly R, Harris W, Wang D, Darbre P. Autocrine production of insulin like growth factor-II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ 1991; 2: 457–464.PubMedGoogle Scholar
  155. 155.
    Cullen K, Lippman M, Chow D, Hill S, Rosen N, Zwiebel J. Insulin-like growth factor-II over expression in MCF-7 cells induces phenotypic chances associated with malignant progression. Mol Endocrinol 1992; 6: 91–100.PubMedGoogle Scholar
  156. 156.
    Daws MR, Westley BR, May FE. Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol. Endocrinology 1996; 137: 1177–1186.PubMedGoogle Scholar
  157. 157.
    Guvakova MA, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 1997; 231: 149–162.PubMedGoogle Scholar
  158. 158.
    Nolan MK, Jankowska L, Prisco M, Xu S, Guvakova MA, Surmacz E. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int J Cancer 1997; 72: 828–834.PubMedGoogle Scholar
  159. 159.
    Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 1998;273: 9994–10, 003.Google Scholar
  160. 160.
    Dufourny B, Alblas J, van Teeffelen HAAM, van Schaik FMA, van der Burg B, Steenbergh PH, Sussenbach JS. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997;272:31, 163–31, 171.Google Scholar
  161. 161.
    Katzenellenbogen B, Norman MJ. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology 1990; 126: 891–898.PubMedGoogle Scholar
  162. 162.
    Cho H, Aronica S, Katzenellenbogen BS. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3’-5’-monophosphate, estradiol, insulin-like growth factor-I and serum factors. Endocrinology 1994; 134: 658–664.PubMedGoogle Scholar
  163. 163.
    Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 1993; 7: 743–752.PubMedGoogle Scholar
  164. 164.
    Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491–1494.PubMedGoogle Scholar
  165. 165.
    Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174–2183.PubMedGoogle Scholar
  166. 166.
    Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997; 152: 39–47.PubMedGoogle Scholar
  167. 167.
    Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF, Korach KS. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci USA 1996;93:12, 626–12, 630.Google Scholar
  168. 168.
    Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10: 1167–1177.PubMedGoogle Scholar
  169. 169.
    Ahmed SR, Manni A, Gray G, Hammond JM. Characterisation and hormonal regulation of radioimmunoassayable IGF-I (insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells. Anticancer Res 1990; 10: 1217–1223.PubMedGoogle Scholar
  170. 170.
    Yee D, Paik S, Levovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989; 3: 509–517.PubMedGoogle Scholar
  171. 171.
    Giani C, Cullen KJ, Campani D, Rasmussen A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 1996; 41: 43–50.PubMedGoogle Scholar
  172. 172.
    Paik S. Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 1992; 22: 31–38.PubMedGoogle Scholar
  173. 173.
    Toropainen EM, Lipponen PK, Syrjanen KJ. Expression of insulin-like growth factor II in human breast cancer as related to established prognostic factors and long-term prognosis. Anticancer Res 1995; 15: 2669–2674.PubMedGoogle Scholar
  174. 174.
    Cullen K, Yee D, Sly W, Perdue J, Hampton B, Lippman M, Rosen N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990; 50: 48–53.PubMedGoogle Scholar
  175. 175.
    Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch T, Cullen KJ. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 1995; 55: 2448–2454.PubMedGoogle Scholar
  176. 176.
    Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 1996; 56: 1509–1511.PubMedGoogle Scholar
  177. 177.
    Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998; 47: 209–217.PubMedGoogle Scholar
  178. 178.
    Westley BR, May FEB. Role of insulin-like growth factors in steroid modulated proliferation. J Steroid Biochem Mol Biol 1994; 51: 1–9.PubMedGoogle Scholar
  179. 179.
    Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGFIR) signaling pathway in breast cancer cells. Cancer Res 1997; 57: 2606–2610.PubMedGoogle Scholar
  180. 180.
    Milazzo G, Giorgino F, Damante G, Sung C, Stampfer M, Vigneri R, Goldfine I, Belfiore A. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992; 52: 3924–3930.PubMedGoogle Scholar
  181. 181.
    Peyrat J-P, Bonneterre J, Beuscart J, Dijane J, Demaille A. Insulin-like growth factor I receptors in human breast cancer and their relationship to estradiol and progesterone receptors. Cancer Res 1988; 48: 6429–6433.PubMedGoogle Scholar
  182. 182.
    Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079–3083.PubMedGoogle Scholar
  183. 183.
    Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998; 58: 1159–1164.PubMedGoogle Scholar
  184. 184.
    Yee D, Sharma J, Hilsenbeck SG. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst 1994; 86: 1785–1789.PubMedGoogle Scholar
  185. 185.
    Swisshelm K, Ryan K, Tsuchiya K, Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA 1995; 92: 4472–4476.PubMedGoogle Scholar
  186. 186.
    Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M, Papas T, Seth A. Down-regulation of TIAl2/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998; 16: 2459–2467.PubMedGoogle Scholar
  187. 187.
    Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in human breast cancer. Br J Cancer 1996; 74: 1242–1247.PubMedGoogle Scholar
  188. 188.
    Papa V, Gliozzo B, Clark G, McGuire W, Moore D, Fujita-Yamaguchi Y, et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993; 53: 3736–3740.PubMedGoogle Scholar
  189. 189.
    Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res 1990; 50: 6931–6935.PubMedGoogle Scholar
  190. 190.
    Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng C-N, Lee AV, Yee D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997; 3: 103–109.PubMedGoogle Scholar
  191. 191.
    Baserga R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotech 1996; 14: 150–152.Google Scholar
  192. 192.
    Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55: 249–252.PubMedGoogle Scholar
  193. 193.
    D’Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996; 56: 4013–4020.PubMedGoogle Scholar
  194. 194.
    Neuenschwander S, Roberts CT, Leroith D. Growth inhibition of human breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995; 136: 4298–4303.PubMedGoogle Scholar
  195. 195.
    Yee D, Jackson JG, Kozelsky TW, Figueroa JA. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 cells. Cell Growth Differ 1994; 5: 73–77.PubMedGoogle Scholar
  196. 196.
    Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989; 49: 6237–6241.PubMedGoogle Scholar
  197. 197.
    Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, Osborne CK. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989; 84: 1418–1423.PubMedGoogle Scholar
  198. 198.
    Brunner N, Yee D, Kern FG, Spangthomsen M, Lippman ME, Cullen KJ. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor-II (IGF-II). Eur J Cancer 1993; 29A: 562–569.Google Scholar
  199. 199.
    Ray BS, Pearson OH. Hypophysectomy in treatment of disseminated breast cancer. Surg Oncol Clin N Am 1962; 12: 419–433.Google Scholar
  200. 200.
    Di Leo A, Ferrari L, Bajetta E, Bartoli C, Vicario G, Moglia D, et al. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. group. Italian Trials in Medical Oncology. Breast Cancer Res Treat 1995; 34: 237–244.Google Scholar
  201. 201.
    Canobbio L, Cannata D, Miglietta L, Boccardo F. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res 1995; 15: 2687–2690.PubMedGoogle Scholar
  202. 202.
    Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthraceneinduced rat mammary carcinomas. Cancer Res 1994; 54: 6334–6337.PubMedGoogle Scholar
  203. 203.
    Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, Braun HI, et al. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with longterm follow-up. Br J Cancer 1998; 77: 115–122.PubMedGoogle Scholar
  204. 204.
    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–744.PubMedGoogle Scholar
  205. 205.
    Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-pl85HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–2671.PubMedGoogle Scholar
  206. 206.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2000

Authors and Affiliations

  • Douglas Yee
  • Adrian V. Lee

There are no affiliations available

Personalised recommendations